Sangamo Therapeutics, Inc.

Good afternoon and welcome to Zagnimo's Therapeutics First Quarter 2026 teleconference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilkie, Head of Investor Relations and Corporate Communications. Ma'am, please go ahead.

Thank you. Good afternoon, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo executive leadership team, including Sandy McRae, Chief Executive Officer, Natalie Dubrov-Stringfellow, Chief Development Officer, and Nikunj Jain, Interim Chief Financial Officer. Slides from our corporate presentation can be found on our website, sangamo.com, and under the Presentations page of the Investors and Media section. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to Sangamo's cash runway, Sangamo's plans to obtain additional capital and its ability to continue to operate as a going concern, the therapeutic and commercial potential and value of Sangamo's product candidates and technologies, Sangamo's ability to establish and maintain collaborations and strategic partnerships, including for its Fabry disease program, the anticipated plans of Sangamo and its collaborators for clinical trials, regulatory submissions, and regulatory approvals, and other statements that are not historical fact. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC, specifically in our annual report on Form 10-K for the fiscal year ended December 31, 2025, and the quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2026, and subsequent filings and reports that Sancoma makes from time to time with the SEC. The forward-looking statements stated today are made as of today, and we undertake no duty to update such information except as required by law. Please note that all forward-looking statements about our future plans and expectations are subject to our ability to secure adequate additional funding. Now, I'll turn the call over to our CEO, Sandy McRae.

Thank you, Louise, and good afternoon to everyone joining the call today. In the short time since our fourth quarter earnings call, we have continued to advance the rolling submission of the BLA for ST920 in Fabry disease, and made progress across our differentiated neurology pipeline. Natalie will provide a detailed update on our development pipeline shortly. This quarter, Sangamo's common stock transitioned to trading on the OTCQB Venture Market, following the receipt of a delisting determination from Nasdaq Capital Markets due to non-compliance with Nasdaq's minimum bid requirements. We intend to appeal the determination at a hearing before Nasdaq in June. Our stock began trading on the OTCQB venture market earlier this month under the same ticker symbol SGMO. While we are disappointed by the NASDAQ delisting determination, the transition to the OTCQB market will allow Sangamo to maintain access to the public markets while we seek to advance our promising development pipeline. We remain focused on pursuing a number of opportunities to raise additional capital, including evaluating all strategic options to maximize the value of Sangamo's assets. Throughout this process, we have been and continue to be supported by a global investment bank. We continue to engage in business development discussions for a potential fabric commercialization agreement, and we'll share more information as appropriate. Before I hand over to Natalie, I'd like to share an update from Boston. where I've just returned, where we had three abstracts accepted this year's American Society of Gene and Cell Therapy annual meeting. ASGCT is an important forum for showcasing innovation in gene and cell therapy, and I was proud to see our talented scientists present our most recent advances in zinc finger epigenetic regulation, specifically for NAV1.7 and prion disease, alongside a platform presentation on our modular integrase technology. We have now achieved impressive levels of targeted integration in a variety of different cell types, moving us one step closer to our aspiration of achieving large-scale genome engineering to integrate large sequences of DNA into the genome. I would like now to hand over to Natalie. Natalie.